Key Data Related to Plexxikon's Lead Oncology Program PLX4032 to be Presented at ASCO 2009 Annual Meeting
Berkeley, CA - May 15, 2009 – Plexxikon Inc., today announced that key data related to PLX4032 and its development, will be presented in three separate presentations at the American Society of Clinical Oncology (ASCO) 2009 Annual Meeting taking place May 29 through June 2, 2009 in Orlando, Florida.
The presentation information is as follows:
- Abstract #9021: “PLX4032, a highly selective BRAFV600E kinase inhibitor: correlation of activity with pharmacokinetic and pharmacodynamic parameters in a Phase 1 trial”
- Poster to be presented on May 31, 2009, 8:00 a.m. – 12:00 p.m. EDT by Igor Puzanov, M.D., assistant professor of medicine, Vanderbilt University Medical Center, in the melanoma poster discussion session
- Abstract #11003: “Selecting subjects for a therapeutic target in colorectal cancer (CRC): Using a clinical database to enrich for patients harboring the BRAFV600E mutation”
- Oral presentation to be made on June 1, 2009, 9:30 a.m. EDT by Jeanne Tie from the Ludwig Institute for Cancer Research in the “Tumor Biology and Human Genetics” session
- Abstract #9000: “Phase 1 study of PLX4032: Proof-of-concept for V600E BRAF mutation as a therapeutic target in human cancer”
- Oral presentation to be made on June 1, 2009, 4:30 p.m. to 6:00 p.m. EDT by Keith T. Flaherty, assistant professor, University of Pennsylvania Abramson Cancer Center, in the “Molecular Phenotype of Melanoma Subtypes and Patient-Specific Therapy” session. Link to video clip of Dr. Flaherty.
About PLX4032 (R7204)—A Personalized Medicine for Cancer Treatment
PLX4032 is a novel, oral small molecule for the treatment of melanoma and other cancers harboring the V600E mutation of the BRAF kinase gene. This defect is present in approximately 60 percent of melanoma skin cancers, and occurs in about eight percent of all solid tumors, including melanoma, colorectal, thyroid and other cancers. Preclinical data suggest that Plexxikon’s novel anti-cancer compound selectively targets and regresses tumors which contain this cancer-causing mutation. In contrast to many other kinase inhibitors available, PLX4032 is highly selective for its primary target, and does not have significant activity on other kinase targets.
Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s clinical stage programs include PLX4032 for the treatment of melanoma and colorectal cancer, PLX5568 for the treatment of polycystic kidney disease and PLX204 for the treatment of diabetes. Among the company’s preclinical development programs, candidates are being developed for the treatment of rheumatoid arthritis, multiple sclerosis and other autoimmune diseases as well as for the treatment of pancreatic and metastatic breast cancer.
Plexxikon’s proprietary Scaffold-Based Drug Discovery™ platform integrates multiple state-of-the-art technologies, including structural screening as one key component that provides a significant competitive advantage over other drug discovery approaches. To date, the company has discovered a portfolio of clinical and preclinical stage compounds being developed to address significant unmet medical needs in cardio-renal disease, CNS disorders, inflammatory and neuro-inflammatory diseases and oncology.